Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle
- 18 November 2015
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (314), 314ra183
- https://doi.org/10.1126/scitranslmed.aac6522
Abstract
Therapeutic nanoparticles (TNPs) have shown heterogeneous responses in human clinical trials, raising questions of whether imaging should be used to identify patients with a higher likelihood of NP accumulation and thus therapeutic response. Despite extensive debate about the enhanced permeability and retention (EPR) effect in tumors, it is increasingly clear that EPR is extremely variable; yet, little experimental data exist to predict the clinical utility of EPR and its influence on TNP efficacy. We hypothesized that a 30-nm magnetic NP (MNP) in clinical use could predict colocalization of TNPs by magnetic resonance imaging (MRI). To this end, we performed single-cell resolution imaging of fluorescently labeled MNPs and TNPs and studied their intratumoral distribution in mice. MNPs circulated in the tumor microvasculature and demonstrated sustained uptake into cells of the tumor microenvironment within minutes. MNPs could predictably demonstrate areas of colocalization for a model TNP, poly(d,l-lactic-co-glycolic acid)-b-polyethylene glycol (PLGA-PEG), within the tumor microenvironment with >85% accuracy and circulating within the microvasculature with >95% accuracy, despite their markedly different sizes and compositions. Computational analysis of NP transport enabled predictive modeling of TNP distribution based on imaging data and identified key parameters governing intratumoral NP accumulation and macrophage uptake. Finally, MRI accurately predicted initial treatment response and drug accumulation in a preclinical efficacy study using a paclitaxel-encapsulated NP in tumor-bearing mice. These approaches yield valuable insight into the in vivo kinetics of NP distribution and suggest that clinically relevant imaging modalities and agents can be used to select patients with high EPR for treatment with TNPs.Keywords
Funding Information
- NIH (R01CA164448, U54-CA151884, 5P50CA086355, HL084312)
- DOD (PC140318)
- Deutsche Forschungsgemeinschaft (DFG) (PF809/1-1)
- David H. Koch-Prostate Cancer Foundation Award in Nanotherapeutics (T32 CA 79443)
This publication has 37 references indexed in Scilit:
- Nanoparticle clearance is governed by Th1/Th2 immunity and strain backgroundJCI Insight, 2013
- Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivoNature Communications, 2013
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the LiteraturePLOS ONE, 2012
- Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent mannerNature Nanotechnology, 2012
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translationChemical Society Reviews, 2012
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivoProceedings of the National Academy of Sciences, 2011
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft modelNuclear Medicine and Biology, 2009
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006